Toxicological scoring of Alzheimer's disease drug huperzine in a guinea pig model

Toxicology Mechanisms and Methods

Volumn 22, Issue 3, 2012, Pages 231-235

  Pohanka, Miroslav ^a,b   Zemek, Filip ^a   Bandouchova, Hana ^c   Pikula, Jiri ^c  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^c UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Huperzine; NMDA receptor; Oxidative stress

Indexed keywords

AMINOTRANSFERASE; CASPASE 3; GLUCOSE; GLUTATHIONE REDUCTASE; HUPERZINE A; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UREA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CEREBELLUM; CHINESE MEDICINE; DRUG DOSE COMPARISON; DRUG INDICATION; ENZYME ACTIVITY; EUROPEAN UNION; FRONTAL LOBE; GLUCOSE BLOOD LEVEL; GUINEA PIG; KIDNEY; LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SPLEEN; TEMPORAL LOBE; TOXICITY TESTING; UNITED STATES; UREA NITROGEN BLOOD LEVEL;

ALANINE TRANSAMINASE; ALKALOIDS; ALZHEIMER DISEASE; ANIMALS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD UREA NITROGEN; BRAIN; CASPASE 3; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE REDUCTASE; GUINEA PIGS; KIDNEY; LIVER; MODELS, ANIMAL; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RISK ASSESSMENT; SESQUITERPENES; SPLEEN; THIOBARBITURIC ACID REACTIVE SUBSTANCES; TOXICITY TESTS;

ANIMALIA; CAVIA;

EID: 84856869571     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2011.635320     Document Type: Article

References (21)

1. Aranda-Abreu GE, Hernández-Aguilar ME, Manzo Denes J, García Hernández LI, Herrera Rivero M. 2011. Rehabilitating a brain with Alzheimer's: A proposal. Clin Interv Aging 6:53-59.
2. Coleman BR, Ratclife RH, Oguntayo SA, Shi X, Doctor BP, Gordon RK, Nambiar MP. 2008. [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem Biol Interact 175:387-395.
3. Finder VH. 2010. Alzheimer's disease: A general introduction and pathomechanism. J Alzheimers Dis 22:5-19.
4. Haigh JR, Johnston SR, Peppernay A, Mattern PJ, Garcia GE, Doctor BP, Gordon RK, Aisen PS. 2008. Protection of red blood cell acetylcholinesterase by oral huperzine A against ex vivo soman exposure: Next generation prophylaxis and sequestering of acetylcholines-terase over butyrylcholinesterase. Chem Biol Interact 175:380-386.
5. Howes MJ, Perry E. 2011. The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 28:439-468.
6. Kaplan B, Çetin F, Elbeg S. 2010. The efects of vitamin C administration, acute food deprivation, and acute food intake on vitamin C levels in diferent brain areas of guinea pigs. Int J Vitam Nutr Res 80:197-204.
7. Li C, Du F, Yu C, Xu X, Zheng J, Xu F, Zhu D. 2004. A sensitive method for the determination of the novel cholinesterase inhibitor ZT-1 and its active metabolite huperzine A in rat blood using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 18:651-656. (Pubitemid 38428877)
8. López-Mirabal HR, Winther JR. 2008. Redox characteristics of the eukaryotic cytosol. Biochim Biophys Acta 1783:629-640.
9. Ma XC, Wang HX, Xin J, Zhang T, Tu ZH. 2003. Efects of huperzine A on liver cytochrome P-450 in rats. Acta Pharmacol Sin 24:831-835. (Pubitemid 36988359)
10. Maturu P, Reddy VD, Padmavathi P, Varadacharyulu N. 2011. Ethanol induced adaptive changes in blood for the pathological and toxicological efects of chronic ethanol consumption in humans. Exp Toxicol Pathol. (In Press).
11. Pohanka M. 2011. Alzheimer's disease and related neurodegenerative disorders: Implication and counteracting of melatonin. J Appl Biomed. J Appl Biomed 9:185-196.
12. Pohanka M, Sobotka J, Svobodova H, Stetina R. 2011a. Investigation of oxidative stress in blood, brain, kidney, and liver after oxime antidote HI-6 application in a mouse experimental model. Drug Chem Toxicol 34:85-91.
13. Pohanka M, Sobotka J, Stetina R. 2011b. Sulfur mustard induced oxidative stress and its alteration by epigallocatechin gallate. Toxicol Lett 201:105-109.
14. Raf MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Tomas R, Aisen PS; Alzheimer's Disease Cooperative Study. 2011. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology 76:1389-1394.
15. Sabbagh MN. 2009. Drug development for Alzheimer's disease: Where are we now and where are we headed? Am J Geriatr Pharmacother 7:167-185.
16. Schliebs R, Arendt T. 2006. The signifcance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113:1625-1644. (Pubitemid 44657659)
17. Wang J, Zhang HY, Tang XC. 2010. Huperzine a improves chronic infammation and cognitive decline in rats with cerebral hypoperfusion. J Neurosci Res 88:807-815.
18. Xiao XQ, Zhang HY, Tang XC. 2002. Huperzine A attenuates amyloid β-peptide fragment 25-35-induced apoptosis in rat cortical neurons via inhibiting reactive oxygen species formation and caspase-3 activation. J Neurosci Res 67:30-36.
19. Zhang RW, Tang XC, Han YY, Sang GW, Zhang YD, Ma YX, Zhang CL, Yang RM. 1991. Drug evaluation of huperzine A in the treatment of senile memory disorders. Zhongguo Yao Li Xue Bao 12:250-252.
20. Zhang HY, Tang XC. 2006. Neuroprotective efects of huperzine A: New therapeutic targets for neurodegenerative disease. Trends Pharmacol Sci 27:619-625. (Pubitemid 44738090)
21. Zhang HY, Yan H, Tang XC. 2008. Non-cholinergic efects of huperzine A: Beyond inhibition of acetylcholinesterase. Cell Mol Neurobiol 28:173-183. (Pubitemid 351253069)